Literature DB >> 24985129

MYC association with cancer risk and a new model of MYC-mediated repression.

Michael D Cole1.   

Abstract

MYC is one of the most frequently mutated and overexpressed genes in human cancer but the regulation of MYC expression and the ability of MYC protein to repress cellular genes (including itself) have remained mysterious. Recent genome-wide association studies show that many genetic polymorphisms associated with disease risk map to distal regulatory elements that regulate the MYC promoter through large chromatin loops. Cancer risk-associated single-nucleotide polymorphisms (SNPs) contain more potent enhancer activity, promoting higher MYC levels and a greater risk of disease. The MYC promoter is also subject to complex regulatory circuits and limits its own expression by a feedback loop. A model for MYC autoregulation is discussed which involves a signaling pathway between the PTEN (phosphatase and tensin homolog) tumor suppressor and repressive histone modifications laid down by the EZH2 methyltransferase.
Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24985129      PMCID: PMC4066640          DOI: 10.1101/cshperspect.a014316

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  59 in total

1.  Looping and interaction between hypersensitive sites in the active beta-globin locus.

Authors:  Bas Tolhuis; Robert Jan Palstra; Erik Splinter; Frank Grosveld; Wouter de Laat
Journal:  Mol Cell       Date:  2002-12       Impact factor: 17.970

2.  BCL2 is a downstream effector of MIZ-1 essential for blocking c-MYC-induced apoptosis.

Authors:  Jagruti H Patel; Steven B McMahon
Journal:  J Biol Chem       Date:  2006-11-01       Impact factor: 5.157

Review 3.  Making myc.

Authors:  J Liu; D Levens
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

Review 4.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

5.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

6.  The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

Authors:  Sari Tuupanen; Mikko Turunen; Rainer Lehtonen; Outi Hallikas; Sakari Vanharanta; Teemu Kivioja; Mikael Björklund; Gonghong Wei; Jian Yan; Iina Niittymäki; Jukka-Pekka Mecklin; Heikki Järvinen; Ari Ristimäki; Mariachiara Di-Bernardo; Phil East; Luis Carvajal-Carmona; Richard S Houlston; Ian Tomlinson; Kimmo Palin; Esko Ukkonen; Auli Karhu; Jussi Taipale; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

7.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

Authors:  Julius Gudmundsson; Patrick Sulem; Andrei Manolescu; Laufey T Amundadottir; Daniel Gudbjartsson; Agnar Helgason; Thorunn Rafnar; Jon T Bergthorsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Jianfeng Xu; Thorarinn Blondal; Jelena Kostic; Jielin Sun; Shyamali Ghosh; Simon N Stacey; Magali Mouy; Jona Saemundsdottir; Valgerdur M Backman; Kristleifur Kristjansson; Alejandro Tres; Alan W Partin; Marjo T Albers-Akkers; Javier Godino-Ivan Marcos; Patrick C Walsh; Dorine W Swinkels; Sebastian Navarrete; Sarah D Isaacs; Katja K Aben; Theresa Graif; John Cashy; Manuel Ruiz-Echarri; Kathleen E Wiley; Brian K Suarez; J Alfred Witjes; Mike Frigge; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; Lambertus A Kiemeney; William B Isaacs; William J Catalona; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

8.  The Myc negative autoregulation mechanism requires Myc-Max association and involves the c-myc P2 minimal promoter.

Authors:  L M Facchini; S Chen; W W Marhin; J N Lear; L Z Penn
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

9.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

Review 10.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

View more
  12 in total

Review 1.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 2.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

3.  Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer.

Authors:  Shikha Suman; Ashutosh Mishra
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

4.  MYC promotes cancer progression by modulating m6 A modifications to suppress target gene translation.

Authors:  Gongwei Wu; Caixia Suo; Ying Yang; Shengqi Shen; Linchong Sun; Shi-Ting Li; Yingli Zhou; Dongdong Yang; Yan Wang; Yongping Cai; Nana Wang; Huafeng Zhang; Yun-Gui Yang; Jie Cao; Ping Gao
Journal:  EMBO Rep       Date:  2021-01-11       Impact factor: 8.807

5.  Promoting roles of long non-coding RNA FAM83H-AS1 in bladder cancer growth, metastasis, and angiogenesis through the c-Myc-mediated ULK3 upregulation.

Authors:  Beibei Liu; Wuyue Gao; Wei Sun; Liqiang Li; Chao Wang; Xiaohuai Yang; Jianmin Liu; Yuanyuan Guo
Journal:  Cell Cycle       Date:  2020-12-08       Impact factor: 4.534

6.  Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.

Authors:  Sarmistha Talukdar; Swadesh K Das; Anjan K Pradhan; Luni Emdad; Xue-Ning Shen; Jolene J Windle; Devanand Sarkar; Paul B Fisher
Journal:  Oncotarget       Date:  2016-08-23

7.  Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.

Authors:  Collin Homer-Bouthiette; Yang Zhao; Lauren B Shunkwiler; Benjamine Van Peel; Elizabeth Garrett-Mayer; Rachael C Baird; Anna I Rissman; Stephen T Guest; Stephen P Ethier; Manorama C John; Patricia A Powers; Jill D Haag; Michael N Gould; Bart M G Smits
Journal:  BMC Cancer       Date:  2018-12-10       Impact factor: 4.430

8.  CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer.

Authors:  Houliang Deng; Xiaowen Guan; Longcai Gong; Jianming Zeng; Hongjie Zhang; Mike Y Chen; Gang Li
Journal:  Sci Rep       Date:  2019-01-17       Impact factor: 4.379

9.  GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21.

Authors:  Joseph L Wiemels; Kyle M Walsh; Adam J de Smith; Catherine Metayer; Semira Gonseth; Helen M Hansen; Stephen S Francis; Juhi Ojha; Ivan Smirnov; Lisa Barcellos; Xiaorong Xiao; Libby Morimoto; Roberta McKean-Cowdin; Rong Wang; Herbert Yu; Josephine Hoh; Andrew T DeWan; Xiaomei Ma
Journal:  Nat Commun       Date:  2018-01-18       Impact factor: 17.694

10.  Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation.

Authors:  Stefano de Pretis; Theresia R Kress; Marco J Morelli; Arianna Sabò; Chiara Locarno; Alessandro Verrecchia; Mirko Doni; Stefano Campaner; Bruno Amati; Mattia Pelizzola
Journal:  Genome Res       Date:  2017-09-13       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.